Glucocorticoids induce ROS/RNS production and DNA damage through an iNOS mediated pathway in breast cancer by Flaherty, Renée L. et al.
RESEARCH ARTICLE Open Access
Glucocorticoids induce production of
reactive oxygen species/reactive nitrogen
species and DNA damage through an iNOS
mediated pathway in breast cancer
Renée L. Flaherty1, Matthew Owen2, Aidan Fagan-Murphy1, Haya Intabli1, David Healy2, Anika Patel1,
Marcus C. Allen1, Bhavik A. Patel1 and Melanie S. Flint1*
Abstract
Background: Psychological stress increases the circulating levels of the stress hormones cortisol and
norepinephrine (NE). Chronic exposure to elevated stress hormones has been linked to a reduced response to
chemotherapy through induction of DNA damage. We hypothesize that stress hormone signalling may induce DNA
damage through the production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) and interference
in DNA repair processes, promoting tumourigenesis.
Methods: Breast cancer cell lines were incubated with physiological levels of cortisol and NE in the presence and
absence of receptor antagonists and inducible nitric oxide synthase (iNOS) inhibitors and DNA damage measured
using phosphorylated γ-H2AX. The rate of DNA repair was measured using comet assays and electrochemical
sensors were used to detect ROS/RNS in the cell lysates from cells exposed to stress hormones. A syngeneic mouse
model was used to assess the presence of iNOS in mammary tumours in stressed versus control animals and
expression of iNOS was examined using western blotting and qRT-PCR.
Results: Acute exposure to cortisol and NE significantly increased levels of ROS/RNS and DNA damage and this
effect was diminished in the presence of receptor antagonists. Cortisol induced DNA damage and the production
of RNS was further attenuated in the presence of an iNOS inhibitor. An increase in the expression of iNOS in
response to psychological stress was observed in vivo and in cortisol-treated cells. Inhibition of glucocorticoid
receptor-associated Src kinase also produced a decrease in cortisol-induced RNS.
Conclusion: These results demonstrate that glucocorticoids may interact with iNOS in a non-genomic manner to
produce damaging levels of RNS, thus allowing an insight into the potential mechanisms by which psychological
stress may impact breast cancer.
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Background
Exposure to hormones released as part of the stress re-
sponse has been linked to an increased risk of diseases
such as hypertension, immune dysfunction and cancer
[1–3]. There are several genetic and environmental fac-
tors that contribute to the formation and metastasis of
tumours [4]; however the risks associated with psycho-
logical and oxidative stress are yet to be fully explored.
The neuroendocrine hormones, glucocorticoids and cat-
echolamines, are able to influence tumour biology
through a number of complex systems and are thought to
play a role in the initiation and progression of cancer [5].
Glucocorticoids can promote cell survival in breast tu-
mours through glucocorticoid receptor-mediated activa-
tion of anti-apoptotic genes [6], and both hormones may
alter the immune response, aiding cancer metastases [7].
Stress hormones are now known to play a role in
DNA damage and repair, potentially affecting oncogenic
transformation [8, 9]. Others have shown that stress hor-
mones can induce DNA damage through the production
of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) capable of interacting with DNA, causing
base changes and strand breaks [10, 11]. Cancers with a
propensity to become metastatic have a progressive in-
crease in ROS, contributing to tumour angiogenesis and
metastasis [12]. Studies have shown that specific ROS/
RNS can sensitise cancer cells to ROS-inducing chemo-
therapy agents [13, 14]. It is thought that catecholamines
have the potential to increase the production of ROS
through β2-adrenergic receptor activation, upregulating
PKA activation and levels of ROS, generating oxidative
phosphorylation within the cell [15]. Additionally, iso-
forms of the enzyme nitric oxide synthase (NOS), which
produce nitric oxide (NO) - a potentially damaging RNS -
are upregulated in certain cancers including breast cancer
[16]. Overexpression of inducible NOS (iNOS) and the
subsequent increase in NO has wide-reaching implica-
tions in the context of malignancy, as NO is involved in
several central signalling pathways regulating survival and
proliferation [17]. Recently the inhibition of iNOS as
a potential treatment in breast cancer has been gath-
ering momentum, with studies showing that iNOS in-
hibition can reduce the growth of tumours [18]. As
such this research seeks to draw together direct links
between stress hormones and the production of dam-
age inducing ROS/RNS through an iNOS-mediated
mechanism in breast cancer.
Functional DNA repair processes are also crucial in
order to maintain the genetic integrity of the cell and
prevent transformation. Previous work suggests that
stress hormones may interact with some DNA repair
pathways, and that this interaction in malignant cells
slows or halts the rate of repair [19, 20]. In particular,
we have shown that the addition of stress hormones
allows circumnavigation of DNA damage cell-cycle
checkpoints [8], thus, the cell is unable to undergo delay
and must replicate with the damaged DNA, increasing
the potential of tumourigenic mutations. Furthermore,
Hara et al. have shown that the binding of catechol-
amines to β2-adrenergic receptors recruits the signal
transducer proteins β-arrestins. These are able to inter-
fere with the DNA damage response of p53 resulting in
down-regulation of normal p53 signalling, another po-
tential mechanism by which deleterious DNA damage is
allowed to accumulate [9].
The literature surrounding the field of stress and
breast cancer supports the notion that stress signalling
has an impact on tumourigenesis; however, the majority
of the work is focused on the effects of chronic stress ex-
posure, and the response to acute exposure to stress
hormones is not as well-documented. This study aims to
test the hypothesis that acute exposure to stress hormones
generates increased levels of ROS/RNS and DNA damage,
and attenuates DNA repair rates and identifies mecha-
nisms through which this occurs. As previously shown,
stress hormones reduce the efficacy of paclitaxel in triple-
negative breast cancer (TNBC) through induction of DNA
damage [21]. As such, several cell lines were chosen based
on their glucocorticoid receptor (GR) expression, in order
to investigate the role of ROS/RNS in DNA damage in
TNBC versus non-TNBC. The TNBC lines MDA-MB-231
and HCC38 were selected based on their differing GR sta-
tus, and MCF-7, an estrogen receptor (ER)-positive (ER+)
cell line was selected due to its similar level of GR expres-
sion to MD-MB-231. These cell lines also possess β2-
adrenergic receptors and are aggressively tumourigenic [8].
The breast epithelial cell line MCF10a was also used.
Methods
Cells and culture conditions
Breast cancer cell lines MDA-MB-231 and MCF-7 were
purchased from ATCC and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, UK) with
10% foetal calf serum (Gibco, UK). HCC38 cells were
also purchased from ATCC and maintained in Roswell
Park Memorial Institute (RPMI) medium (Gibco, UK)
with 10% foetal calf serum (Gibco, UK). The 4 T1 breast
cancer cell lines were kindly donated by Dr. Hideo
Okada (University of California). The 4T1 cells were cul-
tured in DMEM with 4 mM L-glutamine and charcoal-
stripped bovine calf serum (10%). MCF10A cells were
purchased from ATCC and maintained in HuMEC-ready
medium (Thermo Fisher, UK) supplemented with
HuMEC supplement kit (Thermo Fisher, UK). All cell
lines were maintained in humid conditions at 37 °C and
with 5% atmospheric CO2. Cell lines were cultured in fil-
tered tissue culture flasks (Fisher, UK) and passaged
twice weekly when confluency was reached.
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Hormone treatment
Prior to hormone treatment, cells were seeded in 6-well
plates and incubated for 24 h at 37 °C. Cells were treated
with predetermined physiologically relevant concentra-
tions of hormones for all experiments unless stated
otherwise. The growth medium was removed and re-
placed with hydrocortisone (Sigma Aldrich, UK) diluted
from a stock concentration of 10-5 M in medium to a
final concentration of 10-6 M. Norepinephrine (Sigma
Aldrich, UK) was diluted from a stock concentration of
10-3 M dissolved in water to a working concentration of
10-5 M and then in medium to achieve a final concentra-
tion of 10-6 M. Pharmacological blocking of hormone re-
ceptors to determine specificity was achieved by
incubating the cells with the GR antagonist RU486
(Sigma Aldrich, UK) or beta-adrenergic receptor antag-
onist propranolol (Sigma Aldrich, UK). Antagonists were
dissolved first in water and then in medium to achieve a
final concentration of 10-6 M and cells were incubated
in their presence for 30 minutes prior to the addition of
cortisol or norepinephrine, respectively.
Electrochemistry
Fabrication and characterisation of ROS/RNS electrodes
Electrodes were fabricated by modification of a previ-
ously published approach [22]. Briefly, a conductive
composite material made from multiwall carbon nano-
tubes and epoxy resin was packed into the tip of a plas-
tic pipette tip. The tip was placed flat onto a smooth
glass surface and a copper wire was pushed firmly from
the end of the plastic tip until it was approximately
2 mm from the end of the plastic pipette tip and the tip
was left to set. Following this a glass capillary was
inserted over the copper wire and attached to the back
of the pipette tip with superglue, attaching the capillary
and sealing the electrode. The electrode surface was
smoothed, polished and coated in platinum black. The
Pt-black composite electrode was then rinsed three times
with PBS and then deionised (DI) water before being used.
Optimisation and calibration of sensors was achieved by
producing a voltamagram measuring a 1 mM ferrocyanide
solution. Sensors were characterised using stock solutions
and multiple step amperometry was utilised for detection
of the various ROS/RNS species. Recordings were carried
out in a stirred solution of PBS buffer, where a baseline
was achieved and after 10 s a volume of stock solution was
added to make the final concentration of the 10 μM of per-
oxynitrite, DEA-NONOate, hydrogen peroxide and nitrite.
For characterisation studies, the current was monitored for
hydrogen peroxide (H2O2), peroxynitrite (ONOO-), NO
and nitrite (NO2-) at +0.3 V, +0.45 V, +0.62 V and +0.85 V,
respectively. The limit of detection for H2O2 was 3.8 nmol,
for ONOO- it was 4 nmol, for NO it was 3.3 nmol and for
NO2- it was 3.2 nmol.
Detection of ROS/RNS from cancer cell lines
MDA-MB-231, MCF-7 and HCC38 cells were plated at
a density of 5 × 104 per well and incubated for 24 h. In
order to understand the time course during which ROS/
RNS generation occurred, cells were exposed to cortisol
(1 μM) and NE (1 μM) for 15, 30, and 90 minutes. Control
wells were left untreated. Following this period, the
medium was removed and cells lysed using 500 μl lysis
buffer (Trevigen). Lysates were then collected and ROS/
RNS levels were quantified using multiple-step amperome-
try using a stainless steel counter electrode and non-leak
Ag|AgCl reference electrode. Measurements of the current
were obtained at +0.3 V, +0.45 V, +0.62 V and +0.85 V for
a duration of 30 s.
Additional measurements were also carried out in
MDA-MB-231 and MCF-7 cells to understand how
ROS/RNS levels were altered when the cells were incu-
bated with RU486 (1 μM) (GR antagonist), propranolol
(1 μM) (β-adrenergic receptor antagonist) 1400 W dihy-
drochloride (10 μM) (iNOS inhibitor; Tocris, UK), L-
NAME (100 μM) (non-specific NOS inhibitor; Tocris,
UK) and PP2 (10 μM) (Src inhibitor; Abcam, UK) for
30 minutes prior to hormone treatment.
Immunofluorescence
For phospho-γ-H2AX analysis, MDA-MB-231 and MCF-7
cells were plated at a density of 2 × 105 per well onto glass
coverslips in a 6-well plate and incubated for 24 hrs. They
were subsequently exposed to cortisol and NE for 2 h at
37 °C in the presence and absence of RU486 and 1400 W
for half an hour prior to hormone treatment; controls were
left untreated. For GR localisation, MCF-7 cells were incu-
bated with cortisol in the presence and absence of RU486
and PP2 (10 μM) for 20 minutes. Cells were then fixed in
3% paraformaldehyde 2% sucrose (pH 7.2) PBS for 10 mi-
nutes, washed, permeabilised using 0.2% TritonX-100 in
PBS for 2.5 minutes at room temperature and blocked with
2% BSA in PBS for 30 minutes at room temperature (RT).
Incubation with the primary antibody; anti-phospho-
Histone H2AX (1:800 in 2% BSA) (Cell Signalling) oc-
curred for 45 minutes at 37 °C, and anti-GR (1:200 2%
BSA) (Insight Biotech, UK) at 4 °C overnight. Samples were
incubated with the secondary antibody; anti-mouse/rabbit
IgG fluorescein isothiocyanate (FITC) (1:200 in 2% BSA)
(Sigma) at 37 °C for 20 minutes. The slides were stained
and mounted withVectashield and visualised using fluores-
cence microscopy. Fluorescent foci were detected using
confocal microscopy (Leica, Germany) and phospho-γ-
H2AX-positive cells, categorised as >5 foci, expressed as a
percentage of total cells counted.
Comet assay
The comet assay was used to measure DNA damage
(directly) and DNA repair (indirectly): 1 × 106 cells from
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the cell lines MDA-MB-231 and MCF10A were isolated
and exposed to H2O2 (50 mM) (Sigma Aldrich, UK), corti-
sol and NE for 20 minutes. Cells were then either
processed immediately or washed in PBS and incubated at
37 °C for a further 20 minutes to allow DNA repair. Cells
were then mixed with 1.2% low melting-point agarose
(Sigma Aldrich, UK) and pipetted onto slides previously
coated with 0.6% ultrapure agarose (Invitrogen, UK). The
gels were allowed to set at 4 °C and lysed in comet lysis
buffer (Trevigen) before immersion in electrophoresis buf-
fer (50 mM NaOH, 1 mM EDTA, 1% dimethyl sulfoxide
(DMSO)) for 45 minutes. Electrophoresis was carried out
at 25 V for 25 minutes and the slides were neutralised in
0.4 M Tris pH7. Cells were stained with ethidium bromide
and the “comet tails” of 100 cells were scored blind
(Nikon, UK) using a 0–4 scoring system based on the
length of the tails. Scores are expressed as arbitrary units
out of a maximum score of 400.
In vivo studies
Tissue processing from the animal work was performed
by MF at the University of Pittsburgh, USA; the method-
ology has been described previously [23]. All mouse pro-
tocols were approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Pitts-
burgh. Briefly, female BALB/c mice (6 weeks old, weight
20 ± 2 g) were injected with 1 × 105 4 T1 cells/0.2 mL
of PBS into the left mammary fat pad. We used the
4 T1 syngeneic mouse model as described previously
[24]. The 4 T1 tumours grow at the induction site
and metastasise rapidly to the lymph nodes. We se-
lected this model as it is a model of TNBC and is
immune competent. The tumours took 2 weeks to be-
come established, with tumour volumes of approximately
100 mm3. Tumours were measured twice weekly using a
digital calliper and the tumour volumes were calculated
using the formula:
Vol mm3
  ¼ L  W2=2
in which L is length (mm) and W is width (mm).
Mice were randomised into either a stress group or
a no-stress group 3 days before treatment (day -3). At
day 0, groups of mice were either placed individually
in adequately ventilated tubes for 1 h three times a
week (stress) or they experienced no stress (NS). All
mice were killed at 4 weeks. All primary tumours
were harvested at necropsy. All tumours were histo-
logically confirmed by haematoxylin and eosin (H&E)
staining.
Immunohistochemical assessment
Paraffin-embedded breast tumours were cut into 10-
μm-thick transverse sections and stained with H&E.
For immunohistochemical assessment, paraffin sec-
tions were deparaffinised and rehydrated in serial
ethanol. Antigen retrieval was performed with sodium
citrate buffer (10 mM, pH6.5) at 95 °C. Samples were
incubated with 3% hydrogen peroxide and blocking
solution (IHC Select, Millipore) for 1 h. Samples were
further incubated with the primary antibody against
iNOS (1:200 in PBS/BSA; Thermo Scientific) and sub-
sequently washed with PBS-Tween20 (0.2%). Second-
ary antibody and streptavidin-horseradish peroxidase
(HRP) solutions were applied (IHC Select, Millipore)
as per the manufacturer’s instructions, and samples
were stained with 3,3-diaminobenzidine (DAB) and
counterstained with haematoxylin. Images were ob-
tained and scored blind from 0 − 3, where 0 = no
staining, 1 =mild, 2 =moderate and 3 = strong staining.
For immunofluorescence, deparaffinisation and antigen
retrieval were performed as above; sections were incubated
with 0.1% Triton-X for 5 minutes and blocked with 2%
BSA/PBS for 1 h. Sections were incubated with anti-GR
(1:50 in PBS/BSA) (Santa Cruz Biotech, UK) for 1 h at RT,
washed, and incubated with anti-Rabbit-FITC (1:200)
(Sigma Aldrich, UK) for half an hour. Samples were
mounted with Vectashield containing 4',6-diamidino-2-
phenylindole (DAPI) and imaged using confocal micros-
copy (Leica, Germany).
Western blot
MCF-7 cells were plated at a density of 2 × 105 cells per
well in a 6-well plate and were incubated with cortisol
for 30 minutes or 24 h. Cells were then washed twice
with cold PBS and incubated with ice cold radioimmu-
noprecipitation assay (RIPA) buffer (150 mM NaCl, 1%
10 NP40/Igepal, 0.5% NaDoC, 0.1% SDS, 50 mM prote-
ase inhibitor (Sigma Aldrich, UK)) for 1–2 minutes. The
lysates were subsequently spun at 13,000 g for 14 mi-
nutes at 4 °C and the supernatant was collected to be
stored at -20 °C until further use.
A Bradford assay (Sigma Aldrich, UK) was used to
measure total protein concentration and 10 μg of protein
loaded per sample. Samples were resolved on SDS-PAGE
gels (10% resolving and 4.5% stacking) and transferred
onto polyvinylidene fluoride (PVDF) membranes. Mem-
branes were blocked in 10% skimmed milk powder (Mar-
vel) and incubated with the following primary antibodies;
iNOS 1:2000 in 10% milk (Thermo Scientific, UK) and
β-actin 1:3000 (Santa Cruz, USA) overnight at 4 °C.
Membranes were subsequently washed in PBS-T (0.2%
Tween20) and incubated with appropriate secondary
antibodies (Anti-rabbit/mouse, 1:2000, Cell Signalling)
in 5% milk for 1 h at room temperature. The mem-
branes were developed using Amersham ECL Prime
detection kit, which was prepared as per the manu-
facturer’s instructions and exposed to Amersham
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Hyperfilm. The film was then processed using a de-
veloping system (Xograph Compact X4) and imaged
in a Chemi Imager (Alpha Inotech). Images were ana-
lysed using ImageJ software to determine the optical
density of the bands.
For immunoprecipitation MCF-7 and MDA-MB-231
cells were incubated with PP2 (10 μM) for 30 minutes
prior to 30 minutes with cortisol. Samples were immu-
noprecipitated for heat shock protein 90 (HSP90) using
Dynabeads Protein A precipitation kit as per the manu-
facturer’s instructions (Thermo Scientific, UK) and anti-
HSP90 antibody (Santa Cruz, USA). A Bradford assay
(Sigma Aldrich, UK) was used to measure total protein
concentration and 10 μg of protein loaded per sample.
Membranes were incubated with the primary antibody
for SRC 1:2000 in 10% milk (Biosource, UK) and anti-
rabbit secondary 1:5000 in 5% milk.
qRT-PCR
MCF-7 and MCF10A cells were treated with cortisol for
30 minutes and for 24 h (1 μM). For RNA extraction
from tumours, 30 mg of tissue per sample was homoge-
nized. RNA was extracted using an RNeasy Kit (Qiagen,
UK) and cDNA was synthesised using a Quantitect Re-
verse Transcription kit (Qiagen, UK) as per the manufac-
turer’s instructions. A Rotor-Gene SYBR Green (Qiagen,
UK) master mix was prepared according to the manufac-
turer’s instructions using Quantitect Primer Assay for
human NOS2 (Qiagen, UK) or mouse NOS2. The sense
and antisense primers for mouse NOS2 were 5′-
AATGGCAACATCAGGTCGGCCATCACT-3′ and 5′-
GCTGTGTGTCACAGAAGTCTCGAACTC-3′ respect-
ively (Eurofins). cDNA was analysed in the Rotor-Gene
qRT-PCR thermocycler and presented as fold change in
expression normalised against β-actin.
Clinical analysis
The expression of NOS2 and SRC in human breast car-
cinomas was examined using Oncomine Cancer Micor-
array database analysis of the The Cancer Genome Atlas
(TCGA) Breast database (n = 137) and Curtis Breast
database, respectively (n = 1600). Expression was com-
pared between normal breast tissue and invasive breast
carcinoma.
Statistical analysis
Graphpad Prism v5.0 was used for all statistical analysis.
For continuous data assuming normal variance, one-way
analysis of variance was used with Tukey’s multiple com-
parisons test between groups. For discrete data, the
Mann-Whitney test was used. Statistical significance was
determined when the p value was <0.05. All the results
are representative of the mean of three independent
experiments (n = 3), each with three technical replicates
± SEM unless otherwise stated.
Results
Exposure to stress hormones increases ROS/RNS
production in breast cancer cell lines
To determine if stress hormones generate ROS/RNS in
breast cancer cells, a panel of cell lines (MCF-7, MDA-
MB-231 and HCC38) were exposed to physiological con-
centrations of the stress hormones cortisol and NE
(Fig. 1a-f). Electrochemical analysis of cell lysates post hor-
mone treatment revealed that ROS/RNS were generated in
a time-dependent manner in all cell lines at 15, 30 and
90 minutes. Treatment with cortisol produced a significant
rise in RNS in all cell lines, specifically NO2, the stable
product of NO and ONOO- generation. Levels peaked sig-
nificantly at 30 minutes and remained significantly elevated
at 90 minutes in MCF-7 (p < 0.01) (Fig. 1a), MDA-MB-231
(p < 0.001) (Fig. 1b) and HCC38 cells (p < 0.001) (Fig. 1c).
After exposure to NE, hydrogen peroxide (H2O2)
levels in MCF-7 cells peaked at 30 minutes (p < 0.05)
(Fig. 1d). Levels increased immediately and continued
to rise significantly for 90 minutes in MDA-MB-231
(p < 0.001) (Fig. 1e) and HCC38 cells (p < 0.001) (Fig. 1f).
Control measurements of untreated MCF-7 and MDA-
MB-231 cells were taken at 60 minutes to ensure cell
culture practices did not inadvertently generate significant
ROS/RNS (Additional file 1: Figure S1A-B).
MCF-7 and MDA-MB-231 cells were used for further
analyses to represent ER+ and TNBC subtypes. The cells
were incubated with either the GR antagonist (RU486)
or β-AR blocker (propranolol) and either the non-
specific NG-nitro-L-arginine methyl ester (L-NAME) or
specific (1400 W) NOS inhibitors for 30 minutes prior to
hormone exposure. Levels of NO2 were significantly in-
creased in MCF-7 (p < 0.001) and MDA-MB-231 (p < 0.01)
cells exposed to cortisol compared to untreated cells
(Fig. 2a-b). Levels were decreased in response to incubation
with RU486, with a significant reduction seen in MCF-7
(p < 0.001) but not in MDA-MB-231 cells compared to
cells exposed to cortisol. Furthermore, incubation with L-
NAME also blocked the production of NO2 in both cell
lines compared to cortisol (MCF-7 (p < 0.001), MDA-MB-
231 (p < 0.01)) (Fig. 2a-b) and incubation with 1400 W
also blocked NO2 generation in MCF-7 cells (p < 0.001)
(Fig. 2a) and MDA-MB-231 cells (p < 0.01) (Fig. 2b). In re-
sponse to NE, H2O2 increased significantly in MCF-7 cells
(p < 0.05) and MDA-MB-231 cells (p < 0.001) (Fig. 2c-d)
and this effect was negated in the presence of propranolol
(MCF-7 (p < 0.05), MDA-MB-231 (p < 0.001)). Levels of
H2O2 remained unaffected by incubation with NE and
L-NAME in MCF-7 cells (p < 0.05) (Fig. 2c) and were
significantly elevated compared to untreated cells in
MDA-MB-231 (p < 0.001) (Fig. 2d).
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Fig. 2 Electrochemical analysis of reactive oxygen species/reactive nitrogen species in response to stress hormones. MCF-7 (a) and MDA-MB-231
(b) cells were incubated with cortisol (Cort) (1 μM) and RU486 (1 μM). MCF-7 (c) and MDA-MB-231 (d) were also incubated with norepinephrine
(NE) (1 μM), propranolol (1 μM) and non-specific and specific nitric oxide synthase blockers (NG-nitro-L-arginine methyl ester (L-NAME) (100 μM)
and 1400 W(10 μM)) for 30 minutes prior to 30 minutes exposure to stress hormone. Levels of hydrogen peroxide (H2O2) and nitrogen dioxide
(NO2) were measured using electrochemical sensors. Data are mean ± SEM and statistical significance was determined using one-way analysis of
variance (post hoc Tukey multiple comparisons). *Significant increase compared to unstimulated cells: *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 1 Electrochemical analyses of reactive oxygen species/reactive nitrogen species produced in response to stress hormones over time. MCF-7,
MDA-MB-231 and HCC38 cells were incubated with cortisol (1 μM) (a-c) and norepinephrine (1 μM) (d-f) for 15, 30 and 90 minutes. Cell lysates
were collected and electrochemical were sensors used to measure levels of hydrogen peroxide (H2O2), peroxynitrite (OONO
-), nitric oxide (NO)
and nitrogen dioxide (NO2). Data are mean ± SEM and statistical significance was determined using one way analysis of variance (post hoc Tukey
multiple comparisons). *Significant increase compared to baseline: *p < 0.05, **p < 0.01, ***p < 0.001
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Stress hormones induce DNA damage in breast cancer cells
Immunofluorescent quantification of the phosphoryl-
ation of histone H2AX was used as an indicator of DNA
damage in breast cancer cells treated with stress hor-
mones. MDA-MB-231 and MCF-7 cells were incubated
with cortisol and NE at physiologically relevant concen-
trations for 2 h, and with RU486 and the selective iNOS
inhibitor 1400 W. Analysis of the number of cells con-
taining more than 5 fluorescent foci, expressed as a per-
centage of total cells counted, indicated a statistically
significant increase in DNA damage in response to
cortisol in MCF-7 (33%) (p < 0.001) (Fig. 3a) and MDA-
MB-231(37%) (p < 0.001) (Fig. 3b) cells compared to
untreated cells (7.5% and 6.8%, respectively).
The addition of NE also produced a significant increase
(p < 0.001) in DNA damage of 33% in MCF-7 (p < 0.001)
and 35% in MDA-MB-231 (p < 0.001) cells compared to
untreated cells (Fig. 3a-b). Furthermore, in both cell lines
the effect of cortisol was nullified in the presence of
RU486, indicating this effect was receptor-mediated (14%
and 18%; p < 0.01). Incubation with the iNOS inhibitor
prior to cortisol treatment reduced the levels of DNA
damage by greater that 50% in MCF-7 (p < 0.001) and
MDA-MB-231 (p < 0.001) cells, but had no significant ef-
fect on NE-treated cells, suggesting the cortisol but not
NE acts through iNOS to produce damaging RNS. Repre-
sentative phospho-γ-H2AX images for MCF-7 (Fig. 3c)
and MDA-MB-231 (Fig. 3d) cells are shown. MCF10A
cells were also exposed to cortisol and NE and DNA dam-
age was measured using the comet assay (Additional file
2: Figure S2). There was no significant increase in DNA
damage in response to cortisol or NE.
Fig. 3 Stress hormones induce DNA damage and impact repair. MCF-7 cells (a) and MDA-MB-231 cells (b) were incubated with cortisol (Cort)
(1 μM) and norepinephrine (NE) (1 μM) for 2 h in the presence and absence of RU486 (1 μM) and the specific nitric oxide synthase blocker
1400W (10 μM). Cells were immunofluorescently labelled and scored as positive when there were more than five foci. c-d Representative image
of fluorescein isothiocyanate and 4',6-diamidino-2-phenylindole staining in MCF-7 and MDA-MB-231 cells. e MDA-MB-231 cells were exposed to
cortisol (1 μM) and NE (1 μM) for 30 minutes and assessed for DNA damage using the comet assay. Comet tails indicating DNA strand breaks
were visually scored according to intensity (0–4). f Representative comet tails in treated and untreated cells and cells after a 20-minute repair
period. Data are mean ± SEM and significance was determined using one-way analysis of variance (post hoc Tukey multiple comparisons). *Significant
increase compared to the control; †significant decrease compared to cortisol: *p < 0.05, **p < 0.01, ***p < 0.001
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DNA repair is adversely affected after stress hormone
exposure
To understand if stress hormone exposure affects the
ability of the cell to repair DNA we used the comet
assay. DNA repair was monitored by incubating cells
after treatment with stress hormones and measuring the
damage remaining after 20 minutes. MDA-MB-231 cells
were exposed to cortisol and NE for 30 minutes and
DNA damage was assessed; a separate plate of cells was
exposed to cortisol and NE for 30 minutes and incu-
bated for a further 20 minutes in medium alone to allow
DNA repair. Comet tails indicating DNA strand breaks
were visually scored according to intensity (0–4). Similar
to the γ-H2AX assay, a significant increase in DNA
damage was immediately observed compared to the
control after 30 minutes treatment with cortisol and
NE (p < 0.01) (Fig. 3e). Damage was also observed in the
H2O2 control (p < 0.01), and this was reduced after a 20-
minute repair period. However, the levels of DNA damage
in the cells that was allowed to repair post cortisol treat-
ment remained significant compared to the H2O2 DNA
repair control (p < 0.05), indicating less DNA repair. Rep-
resentative images are shown in Fig. 3f.
iNOS expression is upregulated in invasive breast
carcinoma and mammary tumours in mice exposed to
stress
Expression of the gene encoding iNOS (NOS2) was ana-
lysed using Oncomine Cancer Microarray databases. In
invasive breast carcinoma (n = 53) NOS2 expression was
significantly increased (p = 7.19E-9) compared to normal
stromal breast tissue (n = 6) (Fig. 4a). To examine if
iNOS expression was regulated at the gene level, mRNA
was extracted from MCF-7 cells exposed to cortisol for
either 30 minutes or 24 h. A significant increase in levels
of iNOS mRNA was observed at 24 h compared to the
Fig. 4 Expression of inducible nitric oxide synthase (iNOS) is increased in breast carcinoma and mouse mammary tumours in response to stress. a
Oncomine Cancer Mircoarray databases were used to analyse expression of NOS2 in the The Cancer Genome Atlas (TGCA) Breast database (n = 137).
Expression was compared between normal breast tissue (n = 61) and invasive breast carcinoma (n = 79). b MCF-7 cells were exposed to cortisol (1 μM)
for 30 minutes and 24 h and mRNA was extracted. cDNA was synthesised and amplified in the presence of gene-specific primers for NOS2 and β-actin
using qRT-PCR. Cycle threshold (Ct) values for NOS2 were normalised against β-actin and fold change was calculated using the delta-Ct method.
Data are mean ± SEM and significance was determined using one-way analysis of variance (post hoc Tukey multiple comparisons). c The 4T1 mouse
mammary gland cells were transplanted into the fourth mammary fat pad of female BALB/C mice and the animals were randomised into groups
exposed to either acute restrain stress or no stress. Tumours were harvested, fixed in paraffin and sectioned subsequent to immunohistochemical
detection (IHC) of iNOS. Labelling was scored (0–3) according to intensity; representative panels are shown. The Mann-Whitney test was used to
ascertain statistical significance. *Significant increase: *p < 0.05, **p < 0.01, ***p < 0.001
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30-minute time point and the control (p < 0.05) (Fig. 4b).
Western blot analysis of protein extracted from MCF-7
cells indicated no increase in iNOS after 30 minutes ex-
posure to cortisol. However after 24 h exposure there
was a trend towards increased expression (p = 0.15)
(Additional file 3: Figure S3).
Immunohistochemical assessment (IHC) was used to
determine the iNOS protein levels in tumours isolated
from mice injected with 4T1 cells and either exposed to
acute psychological stress or no stress. Paraffin-
embedded sections were incubated with a primary anti-
body against iNOS and the intensity of staining was
scored from 0–3, where 0 = 0% staining, 1 = ≤15%, 2 =
15–50% and 3 = 50–100%. Both the non-stressed (NS)
and stressed groups scored positively for iNOS within the
tumours; however, samples from psychologically stressed
animals displayed a statistically significant (p < 0.001)
higher average IHC score than NS mice (Fig. 4c). The 4T1
tumours from NS and stressed mice were also positively
stained for cytoplasmic and nuclear GR (Additional file 4:
Figure S4). Tumour weight and volume has been previ-
ously published [23]. There was no significant difference
in primary tumour weight or volume between the NS and
acutely stressed groups, which is typical for restraint stress
studies [25].
Glucocorticoid-induced production of RNS is reduced by
Src kinase inhibition
A multi-complex of proteins including heat shock
proteins and Src kinase is associated with the GR in
its ligand-unbound state [26, 27]. Expression of Src
was analysed using Oncomine Cancer Microarray da-
tabases. In invasive breast carcinoma (Curtis Breast
database, n = 1456) Src expression was significantly
increased (p = 1.46^-51) compared to normal breast
tissue (n = 144) (Fig. 5a). MCF-7 cells were incubated
with cortisol alongside the Src inhibitor PP2 and GR-
antagonist RU486. Immunofluorescent analysis shows
cortisol induced translocation of the GR to the nu-
cleus, and this was blocked by incubation with RU486
and PP2 (Fig. 5b). Western blot analysis of cells
treated with cortisol and PP2 and immunoprecipita-
tion for HSP90 confirmed presence of the Src-HSP90
complex (Additional file 5: Figure S5).
To determine if GR-associated Src is involved in the gen-
eration of RNS, electrochemical sensors were used to detect
ROS/RNS in cell lysates in MCF-7 cells. A significant
decrease in NO2 was observed in response to cortisol and
Src inhibitor PP2 compared to cortisol alone (p < 0.001)
(Fig. 5c). Similarly a significant decrease in NO2 was also
observed in response to NE and PP2 compared to NE alone
(p < 0.01) (Fig. 5d). Cortisol and NE in combination have an
additive effect on the generation of NO2, increasing it
significantly compared to the control (p < 0.001), and this
effect was reduced by PP2 (p < 0.001) (Fig. 5e). H2O2
increases in response to cortisol and remained elevated
with the addition of PP2 (Fig. 5f). NE-mediated levels of
H2O2 were unaffected by the addition of PP2 with increases
compared to the control (p < 0.001) (Fig. 5g). Cells treated
with cortisol and NE in combination produced higher levels
of H2O2 when incubated with PP2 than when treated
with cortisol or NE alone (p < 0.001) (Fig. 5h).
Discussion
Our results show that acute exposure to stress hormones
can induce DNA damage and that the efficacy of the
subsequent repair is also affected. Using electrochemical
methods a real-time increase in ROS/RNS was observed
as a result of either cortisol or NE incubation. The abil-
ity of chronic stress hormones exposure to induce DNA
damage in breast cancer has recently been shown by our
group [21]. The results corroborate our assertion that
both catecholamines and glucocorticoids, at physiological
levels, can increase DNA damage through receptor-
mediated signalling. The use of electrochemical analyses
to quantify production of ROS/RNS in response to ferro-
cifens in breast cancer has also been explored previously
[28], indicating that TNBC cells produce ROS/RNS in re-
sponse to stimuli.
Our main findings indicate that the effect of cortisol
on both the production of RNS and DNA damage is
abrogated in the presence of NOS and iNOS inhibitors
(L-NAME and 1400 W). This not only suggests that glu-
cocorticoids induce ROS-mediated DNA damage, but
that they also have a previously unobserved effect on the
activity of iNOS. This is a particularly relevant finding in
breast cancer as the expression of iNOS has been found
to increase in line with tumour grade and progression
[29], indicating that NO activity may drive malignant
growth under certain circumstances [18, 30, 31]. As
such, NOS inhibitors are emerging as an area of investi-
gation for potential treatments to combat the tumori-
genic effects of NO [32]. However, the role of NO in the
pathophysiology of cancer is complex, with low levels
mediating many homeostatic processes and allowing cell
proliferation, while high levels are associated with cyto-
toxicity and can induce apoptosis [33].
It is unclear as to whether or not the rise in NO in re-
sponse to stress hormones is a protective mechanism, or
whether it is as a result of increased cellular activity
caused by DNA damage at this time. However, it is pos-
sible to conclude that the generation of RNS must in
part be influenced by the GR, as the presence of a recep-
tor antagonist reduces both the DNA damage and pro-
duction of RNS. Within the cells lines there is some
variation in the effect of the GR antagonist RU486, with
a more prominent reduction seen in MCF-7 cells. This
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may be attributed to the cell line MCF-7 expressing a
higher percentage of total GRs compared to MDA-MB-
231 cells [21], and to the inhibitory effect of RU484 on
progesterone receptors, also present on MCF-7 but not
MDA-MB-231 cells [34].
The expression of iNOS protein was found to increase
in mammary tumours from mice experiencing chronic
psychological stress compared to non-stressed controls.
In breast cancer cell lines although iNOS mRNA
expression was increased after 24 h exposure to cortisol,
protein expression remained unchanged. The actions of
glucocorticoids have classically been described as gen-
omic, mediated through the GR; however, glucocorti-
coids have been shown to induce almost immediate
non-genomic actions on other signalling processes as a
result of proteins dissociating from the GR complex
[27, 35, 36]. The complex includes proteins such as
HSP90 and Src, a multifunctional protein involved in
Fig. 5 Src expression is increased in breast carcinoma and inhibition of Src blocks cortisol-induced reactive nitrogen species. a Oncomine Cancer
Microarray databases were used to analyse expression of SRC in the Curtis Breast database (n = 1600). Expression was compared between normal
breast tissue (n = 144) and invasive breast carcinoma (n = 1456) (p = 1.46E-51). b MCF-7 cells were exposed to cortisol (Cort) (1 μM) for 20 minutes
and to the glucocorticoid receptor (GR)-antagonist RU486 (1 μM) and Src inhibitor PP2 (10 μM) for 30 minutes. Cells were immunofluorescently
labelled for the GR and counterstained with 4',6-diamidino-2-phenylindole. Representative images are shown. MCF-7 cells were incubated with
cortisol (1 μM) (c, f), norepinephrine (NE) (1 μM) (d, g) or a combination of both (e, h) for 30 minutes after 30 minutes exposure to PP2 (10 μM).
Levels of hydrogen peroxide (H2O2) and nitrogen dioxide (NO2) were measured using electrochemical sensors. Results were analysed using
analysis of variance (post hoc Tukey multiple comparisons). Data are mean ± SEM: *p < 0.05, **p < 0.01, ***p < 0.001
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survival, proliferation and angiogenesis [37]. Src ki-
nases are overexpressed in many cancers including
breast cancer and can be used as metastatic markers
[38, 39]. The activation of Src via phosphorylation as
a result of downstream adrenergic signalling has also
been identified as a key switch in tumour metastases,
with Src implicated in NE-mediated vascular endothe-
lial growth factor (VEGF) and IL-6 production, ultim-
ately promoting invasion and metastases [40].
Furthermore, Src is capable of phosphorylating iNOS
in breast cancer cells, prolonging their half-life and
promoting NO generation [41].
In this study inhibition of Src using PP2 attenuated
the glucocorticoid induced production of RNS; however,
it should be noted that PP2 has also been found to in-
hibit other members of the Src family of protein kinases
[42]. As such our data may suggest a potential mechan-
ism through which glucocorticoid binding to the GR
may indirectly exert a non-genomic effect on iNOS to
produce damaging levels of RNS, a previously unex-
plored action of glucocorticoids (Fig. 6).
Interestingly, DNA damage was not significantly re-
duced in cells exposed to the selective iNOS inhibitor
prior to treatment with NE, indicating that, unlike corti-
sol, NE does not interact with or induce iNOS. More-
over the composition of levels of ROS/RNS produced by
NE-treated samples differed greatly from that of the
samples treated with cortisol. In NE-treated cells a sig-
nificant increase was seen in the generation of H2O2
compared to other ROS/RNS, and this effect was re-
versed through inhibition of the β-adrenergic receptor
using propranolol. The mechanism through which the
β-adrenergic receptor induces the generation of ROS is
still unclear; however, it is thought that this may be as a
result of Gs-PKA signalling [9]. Incubation with both
hormones produces the biggest effect on the production
of RNS (Fig. 5f ), indicating that the mechanisms of
DNA damage and ROS/RNS generation in these two
stress hormones are distinct from each other; however,
in combination they may have an additive effect.
Conclusion
The effects of acute exposure to stress hormones can be
seen to have a significant impact on breast cancer cells,
increasing intracellular levels of ROS/RNS and DNA
damage and negatively affecting repair processes. These
Fig. 6 Potential pathway through which stress hormones may stimulate the production of reactive nitrogen species (RNS)/reactive oxygen species
(ROS). Glucocorticoid (GC) and norepinephrine (NE) induce DNA damage through the production of RNS/ROS. Activation of the glucocorticoid
receptor (GR) may facilitate non-genomic effects on inducible nitric oxide synthase (iNOS) through a post-translational modification. Binding of
glucocorticoids to the GR promotes translocation to the nucleus to act on GR response elements (GRE), facilitating transactivation or transrepression
of genes. Binding also induces conformational changes including dissociation of a multiprotein complex comprising heat shock proteins (HSP) and
Src. Src may then mediate phosphorylation of iNOS extending its half-life and promoting the generation of nitric oxide (NO). H2O2 hydrogen peroxide,
β-AR β-Adrenergic receptor
Flaherty et al. Breast Cancer Research  (2017) 19:35 Page 11 of 13
results also demonstrate that glucocorticoid receptor-
mediated signalling may indirectly interact with iNOS to
produce these damaging levels of RNS. In addition, syn-
thetic glucocorticoids such as dexamethasone are regu-
larly prescribed alongside conventional chemotherapy
for hypersensitivity. With this in mind, the work pre-
sented here provides an important understanding of
how endogenous and exogenous glucocorticoids can
regulate ROS/RNS, which may impact response to
current and emerging treatments. In summary, these
data provide an insight into the potential mechanisms
by which psychological stress, glucocorticoid receptor
signalling and iNOS activity may influence the progres-
sion and treatment of breast cancer.
Additional files
Additional file 1: Figure S1. ROS/RNS detection controls. Untreated
MCF-7 (a) and MDA-MB-231 (b) were incubated alongside treatment
wells and lysed at 0 and 60 minutes. Cell lysates were collected and
electrochemical sensors used to measure levels of hydrogen peroxide
(H2O2) and nitrogen dioxide (NO2). (PPTX 111 kb)
Additional file 2: Figure S2. Stress hormones do not induce DNA
damage or iNOS expression in a non-tumourigenic mammary epithelial
cell line. a MCF10A cells were exposed to cortisol (1 μM) and NE (1 μM)
for 30 minutes and assessed for DNA damage using the Comet assay.
Comet tails indicating DNA strand breaks were visually scored according
to intensity (0–4). Representative images shown. b MCF10A cells were
exposed to cortisol (1 μM) for 30 minutes and 24 h and mRNA extracted.
cDNA was synthesised and amplified in the presence of gene specific
primers for NOS2 and β-actin using qRT-PCR. Ct values for NOS2 were
normalised against β-actin and fold change calculated using the delta-Ct
method. Mean ± SEM is expressed and significance was determined using
one-way ANOVA (post hoc Tukey multiple comparisons); *significant
increase, *p < 0.05, **p < 0.01, ***p < 0.001. Technical replicate (n = 3).
(PPTX 125 kb)
Additional file 3: Figure S3. Expression of iNOS protein is unchanged
in response to cortisol. MCF-7 cells were exposed to cortisol (1 μM) for 30
minutes or 24 h. iNOS protein expression was visualised using western
blotting. Optical density values were normalised against β-actin. Mean ± SEM
is shown. (PPTX 186 kb)
Additional file 4: Figure S4. Glucocorticoid receptor localisation in
mice mammary tumours. The 4T1 mouse mammary gland cells were
transplanted into the fourth mammary fat pad of female BALB/C mice
and the animals randomised into groups either exposed to acute
restraint stress or no stress. Tumours were harvested, fixed in paraffin and
sectioned subsequent to immunofluorescent detection of glucocorticoid
receptor (GR). Representative panels are shown. (PPTX 414 kb)
Additional file 5: Figure S5. Cortisol induces the dissociation of Src from
HSP90. MCF-7 and MDA-MB-231 cells were exposed to cortisol (1 μM) for 30
minutes alongside PP2 (10 μM). Cell lysates were immunoprecipitated for
HSP90 and protein levels of Src were visualised using western blotting.
(PPTX 52 kb)
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